HTR7

Across TCGA pan-cancer cohorts, HTR7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HTR7 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher HTR7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HTR7 expression acts as an unfavorable survival marker.

SARC, LUAD, and GBM are the cancer types where HTR7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.029	0.839	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.202	0.711	.001	12	view →
GBM	OS	Median	All	0.058	0.416	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
COAD	OS	Median	All	0.722	0.871	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HTR7–SARC (OS)

Open the SARC breakdown →